Arvinas (ARVN) Stock Analysis & Winston Score

Arvinas is a biotechnology company that develops experimental medicines to treat cancer and other serious diseases. Instead of using traditional drugs that block proteins, Arvinas uses a technology called PROTAC, which trains the body's own cellular machinery to destroy harmful proteins entirely. The company's main drug candidates target breast cancer and prostate cancer, and its potential customers are patients and healthcare systems worldwide. Arvinas makes money primarily through collaboration agreements and licensing deals with larger pharmaceutical companies — most notably a major partnership with Pfizer — rather than selling approved products yet. The company is based in New Haven, Connecticut, and its PROTAC platform represents a meaningful scientific differentiator in a crowded oncology drug market. However, Arvinas is pre-revenue in a traditional sense and burns significant cash while its drugs move through clinical trials, meaning the biggest risk is whether its lead candidates can prove safe and effective enough to win regulatory approval.